This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Pirarubicin
DrugBank Accession Number
DB11616
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 627.643
Monoisotopic: 627.231575635
Chemical Formula
C32H37NO12
Synonyms
  • Adriamycin, tetrahydropyranyl
  • Pirarubicin
  • Theprubicin
  • THP-Adm
  • THP-Doxorubicin

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Pirarubicin.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Pirarubicin.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Pirarubicin.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Pirarubicin.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Pirarubicin.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pirarubicin.
Allogeneic processed thymus tissueThe therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Pirarubicin.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Pirarubicin.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Pirarubicin.
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Pirarubicin.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Pirarubicin hydrochlorideE7V83174BE95343-20-7ZPHYPKKFSHAVOE-YZIXBPQXSA-N

Categories

ATC Codes
L01DB08 — Pirarubicin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Anthracyclines
Sub Class
Not Available
Direct Parent
Anthracyclines
Alternative Parents
Tetracenequinones / Aminoglycosides / Anthraquinones / O-glycosyl compounds / Tetralins / Anisoles / Aryl ketones / Alkyl aryl ethers / Oxanes / Monosaccharides
show 11 more
Substituents
1,4-anthraquinone / 9,10-anthraquinone / Acetal / Alcohol / Alkyl aryl ether / Alpha-hydroxy ketone / Amine / Amino saccharide / Aminoglycoside core / Anisole
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
D58G680W0G
CAS number
72496-41-4
InChI Key
KMSKQZKKOZQFFG-YXRRJAAWSA-N
InChI
InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21+,22-,31+,32-/m0/s1
IUPAC Name
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yloxy]oxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
SMILES
[H][C@]1(N)C[C@]([H])(O[C@@]2([H])C[C@@](O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=C(C=CC=C2OC)C4=O)C(=O)CO)O[C@@]([H])(C)[C@@]1([H])O[C@]1([H])CCCCO1

References

General References
Not Available
KEGG Drug
D01885
PubChem Compound
11296583
PubChem Substance
347828009
ChemSpider
9471567
RxNav
33764
ChEBI
94770
ChEMBL
CHEMBL2354444
ZINC
ZINC000014087429
Wikipedia
Pirarubicin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatment0.5-14 Year Old Children With Nephroblastoma1
4Unknown StatusTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-cell Lymphoma (AITL) / Enteropathy Associated T-cell Lymphoma (EATCL) / Hepato-splenic T-cell Lymphoma / Peripherial T Cell Lymphoma,Not Otherwise Specified / Subcutaneous Panniculitis Like T Cell Lymphoma1
4Unknown StatusTreatmentBreast Cancer1
4Unknown StatusTreatmentMultiple Myeloma (MM)1
3CompletedTreatmentNeoplasms, Breast1
3Unknown StatusTreatmentHepatocellular Carcinoma2
2Not Yet RecruitingPreventionBladder Recurrence / Upper Tract Urothelial Carcinomas1
2RecruitingPreventionBladder Recurrence / Nephroureterectomy / Upper Tract Urothelial Carcinomas1
2RecruitingPreventionBladder Recurrence / Upper Tract Urothelial Carcinomas1
2RecruitingTreatmentAntineoplastic Combined Chemotherapy Protocols1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.301 mg/mLALOGPS
logP2.06ALOGPS
logP2.05ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)7.99ChemAxon
pKa (Strongest Basic)9.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area204.3 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity157.38 m3·mol-1ChemAxon
Polarizability64.85 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at August 25, 2016 22:58 / Updated at February 21, 2021 18:53